Logo
Repadern PN

Repadern PN

Repadern PN

Aesthetic Medicine Products
  • Manufactured and supplied as an injectable PN/HA skin booster originating from South Korea; publicly available information describes composition and indications but does not provide explicit MHRA authorisation or CE certificate details for this specific product.
  • Marketed to professional aesthetic practitioners as a polynucleotide Containing skin booster; regulatory classification and approval status may vary by country and should be verified locally before use.
Polynucleotide (PN) skin booster injectable

Description

Repadern PN is an advanced injectable skin booster that combines polynucleotides (PN) with both high- and low-molecular-weight hyaluronic acid (H-HA and L-HA) to promote skin regeneration, hydration and elasticity. Designed for professional aesthetic use, it targets the face, neck, décolleté and hands, working at a cellular level to stimulate collagen and elastin production, support tissue repair and improve overall skin quality. Each syringe contains a balanced formulation of 32 mg high-molecular hyaluronic acid, 32 mg low-molecular hyaluronic acid and 10 mg polynucleotide (0.5%), providing a powerful bio-stimulating and hydrating effect. The product is positioned as an innovative solution for achieving youthful, hydrated and revitalised skin, and is used as part of a course of micro-injection treatments performed by trained practitioners.

Bnefits

  • Skin regeneration: stimulates cell repair and renewal, improving overall skin quality and resilience.
  • Hydration boost: deeply moisturises the skin via high- and low-molecular-weight hyaluronic acid, enhancing suppleness and reducing dryness.
  • Elasticity and firmness: supports collagen and elastin production, improving skin elasticity and firmness over time.
  • Anti-ageing effects: helps reduce the appearance of fine lines and wrinkles, contributing to a smoother, more youthful-looking complexion.
  • Brightening action: promotes a more even skin tone and improved radiance by supporting healthy skin turnover and structure.
  • Bio-stimulation: polynucleotides act as bio-stimulators at the extracellular matrix level, helping to remodel and support fibroblasts, keratinocytes and other skin cells.
  • Versatile treatment areas: suitable for the face, neck, décolleté, hands and other indicated areas such as inner arms and abdomen depending on protocol.
  • Suitable for all skin types, particularly ageing, dehydrated or dull skin and individuals seeking improved elasticity and overall skin vitality.

Indications

  • Professional injectable treatment for improving skin quality, hydration and elasticity in the face, neck, décolleté and hands.
  • Ageing or photo-damaged skin showing fine lines, mild to moderate wrinkles and loss of elasticity.
  • Dehydrated, dull or tired-looking skin requiring a boost in moisture and radiance.
  • Skin with uneven tone or texture where bio-stimulation and gentle remodelling are desired.
  • Adjunctive treatment in advanced aesthetic protocols to enhance and maintain results of other aesthetic procedures (e.g. toxins, fillers, peels), according to clinical judgement.
  • Indicated in some protocols for additional areas such as inner arms and abdomen for skin quality improvement, where appropriate and within practitioner training and local regulations.

Composition

  • High-molecular-weight hyaluronic acid (H-HA) 32 mg per 2 ml syringe (molecular weight approximately 1100–1400 kDa).
  • Low-molecular-weight hyaluronic acid (L-HA) 32 mg per 2 ml syringe (molecular weight approximately 80–100 kDa).
  • Polynucleotide (PN) 0.5%: 10 mg pure polynucleotide per 2 ml syringe.
  • Total HA content per syringe: 64 mg (32 mg H-HA + 32 mg L-HA).
  • Formulated as a sterile injectable solution with water for injection and standard excipients suitable for hyaluronic acid/PN skin boosters; no BDDE is stated in the main ingredient description for the HA component.

Formulation

  • Injectable skin booster composed of a combination of high- and low-molecular-weight hyaluronic acid with polynucleotide (PN).
  • Total volume per syringe: 2 ml.
  • Active concentrations per 2 ml syringe: H-HA 32 mg, L-HA 32 mg, PN 10 mg (0.5%).
  • High-molecular HA (1100–1400 kDa) provides structural support and hydration.
  • Low-molecular HA (80–100 kDa) enhances diffusion, tissue penetration and moisture distribution.
  • Polynucleotides act as bio-stimulators supporting extracellular matrix remodelling, collagen synthesis and anti-inflammatory effects.
  • Sterile, injectable, non-cross-linked HA/PN skin booster intended for intradermal or superficial subcutaneous micro-injection by trained professionals, using 27G–30G needles as commonly recommended.

Packaging

  • Each box contains three pre-filled syringes of Repadern PN skin booster (3 × 2 ml).
  • Each 2 ml syringe contains 32 mg high-molecular HA, 32 mg low-molecular HA and 10 mg PN (0.5%).
  • Syringes are supplied sterile for single-patient use and are intended to be used with appropriate 27G–30G needles.
  • Outer carton is branded with the Repadern PN name and indicates that the product is a polynucleotide skin booster with HHA and LHA, including basic product specifications and handling information.
  • Supplied to clinics and practitioners via professional aesthetic distributors such as LPG Clinics Wholesale and other authorised wholesalers.

Usage

  • For professional use only: Repadern PN must be administered exclusively by trained and appropriately licensed healthcare practitioners experienced in injectable skin booster techniques.
  • Pre-treatment assessment: Evaluate the patient’s medical history, skin condition, treatment goals and any contraindications. Obtain informed consent outlining potential risks, benefits and alternative options.
  • Preparation: Cleanse and disinfect the treatment area (face, neck, décolleté, hands or other indicated areas) according to standard aseptic protocols.
  • Product handling: Inspect syringes and packaging for integrity and expiry date before use. Attach a suitable 27G–30G needle securely to the syringe, following standard safety procedures.
  • Injection technique: Administer via micro-injections into the superficial to mid-dermis using techniques such as micro-papular, linear threading or serial puncture, depending on the treatment area and practitioner preference. Distribute the product evenly over the treatment area without overfilling any single point.
  • Treatment areas: Commonly treated areas include face (full face or targeted zones), neck, décolleté and hands. Some protocols also include inner arms or abdomen where skin quality improvement is desired and within practitioner competence.
  • Session frequency: Based on manufacturer and distributor guidance, treatments are typically performed as a series of sessions at intervals of approximately every 1–2 weeks, with the number of sessions tailored to the patient’s needs and practitioner protocol.
  • Post-treatment care: Advise the patient to avoid touching or massaging the treated area unnecessarily for several hours, and to avoid intense heat exposure (sauna, sunbeds), strenuous exercise and alcohol for a short period post-procedure as per clinic protocol. Recommend use of broad-spectrum sunscreen and gentle skincare.
  • Monitoring: Schedule follow-up appointments to assess results, skin response and determine the need for additional sessions or maintenance treatments.
  • Disposal: Dispose of used syringes and needles as clinical sharps waste according to local regulations. Do not reuse any syringe or needle.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, polynucleotides or any other component of the formulation.
  • Presence of active skin infection, inflammation or dermatologic disease at or near the intended injection site (e.g. active acne with pustules, herpes lesions, cellulitis).
  • Systemic infection or acute febrile illness at the time of planned treatment.
  • History of severe allergic reactions or anaphylaxis to injectable products, unless carefully evaluated and treated in an appropriate setting by an experienced clinician.
  • Autoimmune diseases, immunosuppression or other significant systemic conditions where injectable biostimulators may pose additional risk, unless used under specialist supervision after risk–benefit assessment.
  • Pregnancy and breastfeeding, as safety has not been established in these populations.
  • Known tendency to develop keloid or hypertrophic scars, particularly in the proposed treatment areas, without careful consideration by the treating practitioner.
  • Use of anticoagulant or antiplatelet medication or bleeding disorders that significantly increase the risk of bruising or haematoma, unless managed appropriately by the clinician.
  • Any contraindications outlined in the official instructions for use supplied with the product and any local regulatory restrictions on PN/HA skin boosters.

Adverse Effects

  • Common, usually transient injection-site reactions such as redness (erythema), swelling, bruising, tenderness, itching or mild discomfort.
  • Small papules or bumps at injection points that typically resolve over hours to days as the product integrates into the skin.
  • Temporary asymmetry or uneven texture in the treated area, usually improving as swelling subsides and the product distributes.
  • Less common events such as prolonged oedema, persistent nodules, localised inflammation or hypersensitivity reactions.
  • Infection at the injection site if aseptic technique is not strictly followed, potentially requiring medical treatment.
  • Very rare but more serious complications that can occur with injectable products, such as vascular compromise or inadvertent intravascular injection, which may lead to tissue ischaemia and require urgent specialist management.
  • Post-inflammatory hyperpigmentation or scarring in predisposed individuals or if complications occur.
  • Any additional adverse effects described in the product’s official instructions for use; patients should be counselled to report unexpected or persistent reactions promptly.

Storage Conditions

  • Store in a cool, dry place at controlled room temperature as indicated on the product packaging (commonly between 2°C and 25°C).
  • Protect from direct sunlight, heat sources and freezing conditions.
  • Keep the product in its original packaging until use to maintain sterility and protect from light.
  • Do not use after the expiry date printed on the carton and syringes.
  • Do not use if the packaging, blister or syringe is damaged or if the solution appears cloudy or contains particulate matter.
  • Keep out of reach of children and unauthorised persons.
  • Once a syringe has been used for a treatment session, any remaining product should be discarded and not stored for future use.

Duration

Results are typically maintained through a series of sessions performed every 1\u20132 weeks, followed by maintenance sessions as advised by the treating practitioner; the exact duration of effect varies between individuals and depends on factors such as skin condition, treatment protocol and lifestyle.

Onset

Improvement in hydration and skin radiance is often noticeable shortly after treatment, while enhancements in elasticity, firmness and fine lines generally develop progressively over the following weeks with completion of the recommended course of sessions.

Browse more Aesthetic Medicine Products

Top Treatments

Top Cities in the UK